Caspofungin: A major breakthrough in treatment of systemic fungal infections

Journal of Association of Physicians of India

Volumn 54, Issue DEC., 2006, Pages 943-948

  Agarwal, M B ^a   Rathi, S A ^b   Ratho, N ^a   Subramanian, R ^c  

^a BOMBAY HOSPITAL   (India)

^b KJ Somaiya Medical College   (India)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOPEPTIDE;

ASPERGILLUS; CANDIDA; DRUG COMBINATION; DRUG EFFECT; HUMAN; IMMUNE DEFICIENCY; MYCOSIS; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; PEPTIDES, CYCLIC; TREATMENT OUTCOME;

EID: 33947599163     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infectious Diseases 1993;167:1247-51.
2. Groll AH, Shah PM, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infection 1996;33:23-32.
3. Wald A, Leisenring W, et al. Epidemiology of aspergillus infection in a large cohort of patients undergoing bone marrow transplantation. J Infectious Diseases 1997;175:1459-66.
4. Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51.
5. Groll AH, Walsh TJ. Caspofungin : Pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001;10:1545-58.
6. Groll AH, Walsh TJ. MK-0991. Curr Opi Anti-Infect. Invest Drugs 2002;1:334-45.
7. Keating G, Figgitt D. Caspofungin : A reviw of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs 2003;63:2235-63.
8. Hoang A. Caspofungin acetate : An antifungal agent. Am J Health Syst Pharm 2001;58:1206-14.
9. Keating GM, Jarvis B. Caspofungin. Drugs 2001;61:1121-9.
10. Georgopapadakou NH. Update on antifungals targeted to the cell wall : focus on beta-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs 2001;10:269-80.
11. Arikan S, Lozano-Chiu, et al. In vitro synergy of caspofungin and amphotericin B against aspergillus and fusarium spp. Antimicrobial Agents and Chemotherapy 2002;46:245-7.
12. Hajdu R, Thompson R, et al. Preliminary animal pharmacokinetics of the parentaral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997;41:2339-44.
13. MSD-Merck Sharp and Dohme Ltd. Caspofungin MSD : Summary of Product Characteristics. Available at http://.www.eudra.org. 2004.
14. Sanz-Rodrigues C, Lopez-Duarte M, et al. Safety of the concomitant use of caspofungin and cyclosporine A in patients with invasive fungal infections. Bone Marrow Transplant 2004;34:13-20.
15. Arathoon EG, Gotuzzo R, et al. Randomized, double-blind, multicentre study of caspofungin versus amphotericin B for treatment of oropharyngeal and oesophageal candidiasis. Antimicrob Agents Chemother 2002;46:451-7.
16. Villanueva A, Arathoon EG, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidial oesophagitis. Clin Infect Dis 2001;33:1529-35.
17. Villanueva A, Gotuzo E, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of oesophageal candidiasis. Am J Med 2002;113:294-9.
18. Mora-Duarte J, Betts R, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-29.
19. Walsh TJ, Teppler, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
20. Maertens J, Raad I, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563-71.
21. Lin SJ, Schranz J, et al. Aspergillosis case-fatality rate : systematic review of the literature. Clin Infect Dis 2001;32:358-66.
22. Hughes Weight, Armstrong D, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
23. Glasmacher A, Cornely OA, et al. Efficacy of caspofungin in neutropenic and non-neutropenic patients (Abstract). Bone Marrow Transplant 2003;31:533.
24. Sanz-Rodrigues C, Martino R, et al. Caspofungin therapy in documented fungal infections in patients with haematological disorders : Spanish experience before licensure of the drug. Blood 2002;100:630a (abstract).
25. Morrissey CO, Slavin MA, et al. Caspofungin as salvage therapy for invasive aspergillosis : results of the Australian compassionate access program. Proc Intesrsci Conf Antimicrob Agents Chemother 2004 (abstract).
26. Letscher-Bru V, Herbrecht R. Caspofungin : The first representative of a new antifungal class. J Anticrob Chemother 2003;51:513-21.
27. Pancham S, Hemmaway C, et al. Caspofungin for invasive fungal infections : combination treatment with liposomal amphotericin B in children undergoing haematopoietic stem cell transplantation. Pediatr Transplantation 2005;9:254-57.
28. Rubin MA, Carroll KC, et al. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clinical Infectious Diseases 2002;34:1160-1.